Angiotensin Therapeutic Vaccine for hypertension
Product information: Hypertension, or high blood pressure, is a major cause of heart attacks, strokes, heart failure, blood vessel problems and kidney damage in the developed world. It is estimated that nearly one in three adults in the US suffer from high blood pressure*. It is therefore not surprising that one in five deaths in the US are a result of coronary heart disease, causing up to 450,000 deaths annually, while a further 160,000 people die from strokes. Current treatments require daily doses of tablets or capsules, usually for life, and while effective when taken regularly, patient compliance is poor.
Angiotensin Therapeutic Vaccine (ATV) may require administration by injection only several times a year, providing an opportunity to improve patient compliance. Clinical studies have shown that ATV is well tolerated when formulated with Alhydrogel® and encouraging effects on the hormones regulating blood pressure were observed. We believe that our new formulation of ATV containing our promising adjuvant, CoVaccine HT™, will produce a stronger immune response to provide a reduction of blood pressure in hypertensive patients.
Technology: Therapeutic peptide conjugate vaccine mixed with novel adjuvant (CoVaccine HT)
Mechanisms of action: Induces antibodies to Angiotensin I, a hormone involved in the regulation of blood pressure
Incidence: One in three people in the US suffer from hypertension
Market opportunity: Up to US$36 billion worldwide per annum**
*American Heart Association
**Protherics estimates of total annual antihypertensive medication sales
We intend to out-license Angiotensin Therapeutic Vaccine following the successful conclusion of the planned Phase 2a study. Please contact our
Business Development team for more information on the Angiotensin Therapeutic Vaccine licensing opportunity.
For further infromation see the
Angiotensin Therapeutic Vaccine fact sheet.